{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02117024",
      "OrgStudyIdInfo": {
        "OrgStudyId": "HS110-201"
      },
      "Organization": {
        "OrgFullName": "Heat Biologics",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer",
      "OfficialTitle": "A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2020",
      "OverallStatus": "Terminated",
      "WhyStopped": "Sponsor Decision; strategic - based on changing treatment landscape",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2014"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2017",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "April 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "April 15, 2014",
      "StudyFirstSubmitQCDate": "April 16, 2014",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 17, 2014",
        "StudyFirstPostDateType": "Estimate"
      },
      "ResultsFirstSubmitDate": "April 26, 2019",
      "ResultsFirstSubmitQCDate": "January 24, 2020",
      "ResultsFirstPostDateStruct": {
        "ResultsFirstPostDate": "February 5, 2020",
        "ResultsFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 24, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 5, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Heat Biologics",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.",
      "DetailedDescription": "This study will test whether vaccination with viagenpumatucel-L combined with low-dose cyclophosphamide will prolong the survival of patients with non-small cell lung cancer (NSCLC) who have failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone. Patients will be randomized 2 to 1 into the viagenpumatucel-L arm and the chemotherapy alone arm, respectively."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Non Small Cell Lung Cancer"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "lung",
          "cancer",
          "gp96",
          "vaccine",
          "immunotherapy",
          "Heat Biologics",
          "cyclophosphamide",
          "vinorelbine",
          "erlotinib",
          "gemcitabine",
          "paclitaxel",
          "docetaxel",
          "pemetrexed"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "66",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Viagenpumatucel-L",
                "Drug: Metronomic Cyclophosphamide"
              ]
            }
          },
          {
            "ArmGroupLabel": "Chemotherapy Alone",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Patients will be treated with a physician's choice regimen until progression.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Viagenpumatucel-L",
            "InterventionDescription": "Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Viagenpumatucel-L Plus Metronomic Cyclophosphamide"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "HS-110"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Metronomic Cyclophosphamide",
            "InterventionDescription": "One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Viagenpumatucel-L Plus Metronomic Cyclophosphamide"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)",
            "InterventionDescription": "Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Chemotherapy Alone"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Overall Survival (OS)",
            "PrimaryOutcomeDescription": "Overall survival (OS) calculated as the duration of survival from the date of randomization to the date of death from any cause, or was censored on the date the patient was last known to be alive.\n\nSurvival time was calculated from the randomization date up to the date of death,or censored on the date that the patient was last known to be alive (last available visit date) utilizing Kaplan-Meier Estimate of Overall Survival Ending Events",
            "PrimaryOutcomeTimeFrame": "Up to 3 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Frequency of Adverse Events: Number of Participants With Treatment-Emergent Adverse Events (TEAE)",
            "SecondaryOutcomeDescription": "Evaluate the safety of the combination of viagenpumatucel-L and low-dose cyclophosphamide by frequency of Treatment-Emergent Adverse Events",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Disease Control Rate (DCR)",
            "SecondaryOutcomeDescription": "Evaluate overall immune-related DCR (irDCR) and also DCR by Response Evaluation Criteria in Solid Tumors (RECIST) (complete response, partial response, and stable disease)",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "6-Month Disease Control Rate (6mDCR)",
            "SecondaryOutcomeDescription": "Evaluate 6-month immune-related DCR (6m-irDCR) and also 6mDCR by RECIST (complete response, partial response, and stable disease at 6 months following randomization)",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Overall Response Rate (ORR)",
            "SecondaryOutcomeDescription": "Evaluate immune-related ORR (irORR) and also ORR by RECIST (complete response and partial response)",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Progression-Free Survival (PFS)",
            "SecondaryOutcomeDescription": "Evaluate immune-related PFS (irPFS) and PFS by RECIST (Response Evaluation Criteria for Solid Tumors)",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Time to Progression (TTP)",
            "SecondaryOutcomeDescription": "Evaluate immune-related TTP (irTTP) and also TTP (Time to Progression) by RECIST",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          },
          {
            "SecondaryOutcomeMeasure": "Survival at 6 Months",
            "SecondaryOutcomeDescription": "Evaluate the proportion of patients who are alive at 6 months following randomization",
            "SecondaryOutcomeTimeFrame": "6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Survival at 12 Months",
            "SecondaryOutcomeDescription": "Evaluate the proportion of patients who are alive at 12 months following randomization",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Immune Response",
            "SecondaryOutcomeDescription": "Characterize the peripheral blood immunologic response via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on cluster of differentiation 8 positive (CD8+) cells following vaccination",
            "SecondaryOutcomeTimeFrame": "Up to 3 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nNon-small cell lung adenocarcinoma\nAt least 2 and no more than 3 prior lines of therapy for incurable or metastatic NSCLC\nSuitable for conventional single agent chemotherapy\nDisease progression at study entry\nEastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1; PS=2 patients may be considered\nCentral nervous system (CNS) metastases may be permitted but must be treated and neurologically stable\nAdequate laboratory parameters\nWilling and able to comply with the protocol and sign informed consent\nFemale patients who are of childbearing potential and fertile male patients must agree to use an effective form of contraception throughout study participation\n\nExclusion Criteria:\n\nReceived systemic anticancer therapy or radiation therapy within the previous 14 days\nReceived more than 3 lines of prior conventional therapy for advanced disease\nHuman immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy\nAny condition requiring concurrent systemic immunosuppressive therapy\nKnown immunodeficiency disorders\nKnown leptomeningeal disease\nOther active malignancies\nPrior treatment with a cancer vaccine for this indication\nPregnant or breastfeeding",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Roger Cohen, MD",
            "OverallOfficialAffiliation": "University of Pennsylvania",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Highlands Oncology Group",
            "LocationCity": "Rogers",
            "LocationState": "Arkansas",
            "LocationZip": "72758",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of California San Diego",
            "LocationCity": "La Jolla",
            "LocationState": "California",
            "LocationZip": "92093",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of California at Los Angeles",
            "LocationCity": "Los Angeles",
            "LocationState": "California",
            "LocationZip": "90029",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of California Davis",
            "LocationCity": "Sacramento",
            "LocationState": "California",
            "LocationZip": "95817",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Georgia Regents University",
            "LocationCity": "Augusta",
            "LocationState": "Georgia",
            "LocationZip": "30912",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Maryland Greenebaum Cancer Center",
            "LocationCity": "Baltimore",
            "LocationState": "Maryland",
            "LocationZip": "21201",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Massachusetts",
            "LocationCity": "Worcester",
            "LocationState": "Massachusetts",
            "LocationZip": "01655",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Washington University School of Medicine",
            "LocationCity": "Saint Louis",
            "LocationState": "Missouri",
            "LocationZip": "63110",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "SUNY Syracuse",
            "LocationCity": "Syracuse",
            "LocationState": "New York",
            "LocationZip": "13210",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Gabrail Cancer Center",
            "LocationCity": "Canton",
            "LocationState": "Ohio",
            "LocationZip": "44718",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Providence Portland Medical Center- Providence Lung Cancer Clinic",
            "LocationCity": "Portland",
            "LocationState": "Oregon",
            "LocationZip": "97213",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Pennsylvania",
            "LocationCity": "Philadelphia",
            "LocationState": "Pennsylvania",
            "LocationZip": "19104",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Texas Oncology PA Texas Cancer Center",
            "LocationCity": "Abilene",
            "LocationState": "Texas",
            "LocationZip": "79606",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Mary Crowley Cancer Center",
            "LocationCity": "Dallas",
            "LocationState": "Texas",
            "LocationZip": "75201",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Cancer Care Northwest",
            "LocationCity": "Spokane",
            "LocationState": "Washington",
            "LocationZip": "99216",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Aurora Research Institute",
            "LocationCity": "Green Bay",
            "LocationState": "Wisconsin",
            "LocationZip": "54311",
            "LocationCountry": "United States"
          }
        ]
      }
    }
  },
  "ResultsSection": {
    "ParticipantFlowModule": {
      "FlowGroupList": {
        "FlowGroup": [
          {
            "FlowGroupId": "FG000",
            "FlowGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
            "FlowGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
          },
          {
            "FlowGroupId": "FG001",
            "FlowGroupTitle": "Chemotherapy Alone",
            "FlowGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
          }
        ]
      },
      "FlowPeriodList": {
        "FlowPeriod": [
          {
            "FlowPeriodTitle": "Overall Study",
            "FlowMilestoneList": {
              "FlowMilestone": [
                {
                  "FlowMilestoneType": "STARTED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "45"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "21"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "1"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowMilestoneType": "NOT COMPLETED",
                  "FlowAchievementList": {
                    "FlowAchievement": [
                      {
                        "FlowAchievementGroupId": "FG000",
                        "FlowAchievementNumSubjects": "44"
                      },
                      {
                        "FlowAchievementGroupId": "FG001",
                        "FlowAchievementNumSubjects": "20"
                      }
                    ]
                  }
                }
              ]
            },
            "FlowDropWithdrawList": {
              "FlowDropWithdraw": [
                {
                  "FlowDropWithdrawType": "Progressive Disease",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "26"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "9"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Significant Clinical Progression",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "7"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "4"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Death",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "5"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Withdrawal by Subject",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "3"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Protocol Violation",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Adverse Event",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "2"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Randomized in Error",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "1"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "0"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Patient returned to primary oncologist",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Patient took treatment break",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "1"
                      }
                    ]
                  }
                },
                {
                  "FlowDropWithdrawType": "Physician Decision",
                  "FlowReasonList": {
                    "FlowReason": [
                      {
                        "FlowReasonGroupId": "FG000",
                        "FlowReasonNumSubjects": "0"
                      },
                      {
                        "FlowReasonGroupId": "FG001",
                        "FlowReasonNumSubjects": "2"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "BaselineCharacteristicsModule": {
      "BaselinePopulationDescription": "Sixty-six of the original 123 planned patients were enrolled from June 2014 to 10 September 2015. Patients were randomized in a 2:1 ratio in the experimental group (n=45) and the control group (n=21). Sixty-three patients were included in the safety population.",
      "BaselineGroupList": {
        "BaselineGroup": [
          {
            "BaselineGroupId": "BG000",
            "BaselineGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
            "BaselineGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
          },
          {
            "BaselineGroupId": "BG001",
            "BaselineGroupTitle": "Chemotherapy Alone",
            "BaselineGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
          },
          {
            "BaselineGroupId": "BG002",
            "BaselineGroupTitle": "Total",
            "BaselineGroupDescription": "Total of all reporting groups"
          }
        ]
      },
      "BaselineDenomList": {
        "BaselineDenom": [
          {
            "BaselineDenomUnits": "Participants",
            "BaselineDenomCountList": {
              "BaselineDenomCount": [
                {
                  "BaselineDenomCountGroupId": "BG000",
                  "BaselineDenomCountValue": "45"
                },
                {
                  "BaselineDenomCountGroupId": "BG001",
                  "BaselineDenomCountValue": "21"
                },
                {
                  "BaselineDenomCountGroupId": "BG002",
                  "BaselineDenomCountValue": "66"
                }
              ]
            }
          }
        ]
      },
      "BaselineMeasureList": {
        "BaselineMeasure": [
          {
            "BaselineMeasureTitle": "Age, Categorical",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "<=18 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Between 18 and 65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "21"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "12"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "33"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": ">=65 years",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "24"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "9"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "33"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Age, Continuous",
            "BaselineMeasureParamType": "Mean",
            "BaselineMeasureDispersionType": "Standard Deviation",
            "BaselineMeasureUnitOfMeasure": "years",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "65.6",
                              "BaselineMeasurementSpread": "8.9"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "63.0",
                              "BaselineMeasurementSpread": "10.5"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "64.8",
                              "BaselineMeasurementSpread": "9.4"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Sex: Female, Male",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Female",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "27"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "10"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "37"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Male",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "18"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "11"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "29"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Not Hispanic or Latino",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "44"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "21"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "65"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Race (NIH/OMB)",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineCategoryTitle": "American Indian or Alaska Native",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Asian",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Black or African American",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "2"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "2"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "White",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "44"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "18"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "62"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "More than one race",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "0"
                            }
                          ]
                        }
                      },
                      {
                        "BaselineCategoryTitle": "Unknown or Not Reported",
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "1"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "0"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "1"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "BaselineMeasureTitle": "Region of Enrollment",
            "BaselineMeasureParamType": "Count of Participants",
            "BaselineMeasureUnitOfMeasure": "Participants",
            "BaselineClassList": {
              "BaselineClass": [
                {
                  "BaselineClassTitle": "United States",
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "38"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "18"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "56"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "BaselineClassTitle": "Australia",
                  "BaselineCategoryList": {
                    "BaselineCategory": [
                      {
                        "BaselineMeasurementList": {
                          "BaselineMeasurement": [
                            {
                              "BaselineMeasurementGroupId": "BG000",
                              "BaselineMeasurementValue": "7"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG001",
                              "BaselineMeasurementValue": "3"
                            },
                            {
                              "BaselineMeasurementGroupId": "BG002",
                              "BaselineMeasurementValue": "10"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "OutcomeMeasuresModule": {
      "OutcomeMeasureList": {
        "OutcomeMeasure": [
          {
            "OutcomeMeasureType": "Primary",
            "OutcomeMeasureTitle": "Overall Survival (OS)",
            "OutcomeMeasureDescription": "Overall survival (OS) calculated as the duration of survival from the date of randomization to the date of death from any cause, or was censored on the date the patient was last known to be alive.\n\nSurvival time was calculated from the randomization date up to the date of death,or censored on the date that the patient was last known to be alive (last available visit date) utilizing Kaplan-Meier Estimate of Overall Survival Ending Events",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "Days",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "45"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "21"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "176",
                              "OutcomeMeasurementLowerLimit": "114.0",
                              "OutcomeMeasurementUpperLimit": "231.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "372",
                              "OutcomeMeasurementLowerLimit": "204.0",
                              "OutcomeMeasurementUpperLimit": "875.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeAnalysisList": {
              "OutcomeAnalysis": [
                {
                  "OutcomeAnalysisGroupIdList": {
                    "OutcomeAnalysisGroupId": [
                      "OG000",
                      "OG001"
                    ]
                  },
                  "OutcomeAnalysisNonInferiorityType": "Superiority",
                  "OutcomeAnalysisPValue": "0.0011",
                  "OutcomeAnalysisStatisticalMethod": "Log Rank"
                },
                {
                  "OutcomeAnalysisGroupIdList": {
                    "OutcomeAnalysisGroupId": [
                      "OG000",
                      "OG001"
                    ]
                  },
                  "OutcomeAnalysisGroupDescription": "With only 50% of enrollment complete prior to study termination by sponsor, insufficient sample size exists to fully complete efficacy analysis.",
                  "OutcomeAnalysisNonInferiorityType": "Other",
                  "OutcomeAnalysisPValue": "<0.05",
                  "OutcomeAnalysisStatisticalMethod": "Other",
                  "OutcomeAnalysisParamType": "Hazard Ratio (HR)",
                  "OutcomeAnalysisParamValue": "1.0",
                  "OutcomeAnalysisCINumSides": "2-Sided"
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Frequency of Adverse Events: Number of Participants With Treatment-Emergent Adverse Events (TEAE)",
            "OutcomeMeasureDescription": "Evaluate the safety of the combination of viagenpumatucel-L and low-dose cyclophosphamide by frequency of Treatment-Emergent Adverse Events",
            "OutcomeMeasurePopulationDescription": "Safety was defined as the number of adverse events (AE)/serious adverse events (SAE) in patients receiving viagenpumatucel-L and low-dose Cyclophosphamide (CY).",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "43"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "20"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "At least one TEAE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "41"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "20"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "At least one severe TEAE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "25"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "11"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "At least one treatment-related TEAE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "32"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "15"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "At least one SAE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "17"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "8"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Fatal TEAE",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "7"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "At least one TEAE Leading to Tx Discontinuation",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "7"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "At least one TEAE Leading to a Dose Reduction",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "2"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Disease Control Rate (DCR)",
            "OutcomeMeasureDescription": "Evaluate overall immune-related DCR (irDCR) and also DCR by Response Evaluation Criteria in Solid Tumors (RECIST) (complete response, partial response, and stable disease)",
            "OutcomeMeasurePopulationDescription": "Data were not collected for Outcome Measure 3 due to study termination (50% enrollment) by the Sponsor on 01 September 2015 due to changing treatment landscape (PD-1 approvals), and a subsequent change in development focus to Immuno-Oncology (IO) combinations. See NCT02439450.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "6-Month Disease Control Rate (6mDCR)",
            "OutcomeMeasureDescription": "Evaluate 6-month immune-related DCR (6m-irDCR) and also 6mDCR by RECIST (complete response, partial response, and stable disease at 6 months following randomization)",
            "OutcomeMeasurePopulationDescription": "Data were not collected for Outcome Measure 4 due to study termination (50% enrollment) by the Sponsor on 01 September 2015 due to changing treatment landscape (PD-1 approvals), and a subsequent change in development focus to Immuno-Oncology (IO) combinations. See NCT02439450.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "6 months",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Overall Response Rate (ORR)",
            "OutcomeMeasureDescription": "Evaluate immune-related ORR (irORR) and also ORR by RECIST (complete response and partial response)",
            "OutcomeMeasurePopulationDescription": "Data were not collected for Outcome Measure 5 due to study termination (50% enrollment) by the Sponsor on 01 September 2015 due to changing treatment landscape (PD-1 approvals), and a subsequent change in development focus to Immuno-Oncology (IO) combinations. See NCT02439450.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Progression-Free Survival (PFS)",
            "OutcomeMeasureDescription": "Evaluate immune-related PFS (irPFS) and PFS by RECIST (Response Evaluation Criteria for Solid Tumors)",
            "OutcomeMeasurePopulationDescription": "Calculated from randomization date to earliest date of first 'Progressive Disease' response (Immune-Related / RECIST Response Criteria) or date of death, and censored on the date of the last available post-baseline tumor assessment.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "Days",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "45"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "21"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "immune-related PFS (irPFS)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "76.0",
                              "OutcomeMeasurementLowerLimit": "66.0",
                              "OutcomeMeasurementUpperLimit": "106.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "190.0",
                              "OutcomeMeasurementLowerLimit": "72.0",
                              "OutcomeMeasurementUpperLimit": "445.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Progression Free Survival (PFS)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "70.0",
                              "OutcomeMeasurementLowerLimit": "65.0",
                              "OutcomeMeasurementUpperLimit": "96.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "190.0",
                              "OutcomeMeasurementLowerLimit": "72.0",
                              "OutcomeMeasurementUpperLimit": "317.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Time to Progression (TTP)",
            "OutcomeMeasureDescription": "Evaluate immune-related TTP (irTTP) and also TTP (Time to Progression) by RECIST",
            "OutcomeMeasurePopulationDescription": "Time to immune-related progression was calculated from the randomization date up to the date of the first 'Progressive Disease' response (Immune-Related Response Criteria) Time to progression was calculated from the randomization date up to the date of the first 'Progressive Disease' response (RECIST Response Criteria).",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Median",
            "OutcomeMeasureDispersionType": "95% Confidence Interval",
            "OutcomeMeasureUnitOfMeasure": "Days",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "45"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "21"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeClassTitle": "immune-related TTP (irTTP)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "67.0",
                              "OutcomeMeasurementLowerLimit": "61.0",
                              "OutcomeMeasurementUpperLimit": "76.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "71.0",
                              "OutcomeMeasurementLowerLimit": "64.0",
                              "OutcomeMeasurementUpperLimit": "155.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                },
                {
                  "OutcomeClassTitle": "Time to Progression (TTP)",
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "67.5",
                              "OutcomeMeasurementLowerLimit": "64.0",
                              "OutcomeMeasurementUpperLimit": "76.0"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "73.5",
                              "OutcomeMeasurementLowerLimit": "64.0",
                              "OutcomeMeasurementUpperLimit": "198.0"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Survival at 6 Months",
            "OutcomeMeasureDescription": "Evaluate the proportion of patients who are alive at 6 months following randomization",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "6 months",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "45"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "21"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "21"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "17"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Survival at 12 Months",
            "OutcomeMeasureDescription": "Evaluate the proportion of patients who are alive at 12 months following randomization",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureParamType": "Count of Participants",
            "OutcomeMeasureUnitOfMeasure": "Participants",
            "OutcomeMeasureTimeFrame": "12 months",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "45"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "21"
                      }
                    ]
                  }
                }
              ]
            },
            "OutcomeClassList": {
              "OutcomeClass": [
                {
                  "OutcomeCategoryList": {
                    "OutcomeCategory": [
                      {
                        "OutcomeMeasurementList": {
                          "OutcomeMeasurement": [
                            {
                              "OutcomeMeasurementGroupId": "OG000",
                              "OutcomeMeasurementValue": "8"
                            },
                            {
                              "OutcomeMeasurementGroupId": "OG001",
                              "OutcomeMeasurementValue": "11"
                            }
                          ]
                        }
                      }
                    ]
                  }
                }
              ]
            }
          },
          {
            "OutcomeMeasureType": "Secondary",
            "OutcomeMeasureTitle": "Immune Response",
            "OutcomeMeasureDescription": "Characterize the peripheral blood immunologic response via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on cluster of differentiation 8 positive (CD8+) cells following vaccination",
            "OutcomeMeasurePopulationDescription": "Data were not collected for Outcome Measure 10 due to study termination (50% enrollment) by the Sponsor on 01 September 2015 due to changing treatment landscape (PD-1 approvals), and a subsequent change in development focus to Immuno-Oncology (IO) combinations. See NCT02439450.",
            "OutcomeMeasureReportingStatus": "Posted",
            "OutcomeMeasureTimeFrame": "Up to 3 years",
            "OutcomeGroupList": {
              "OutcomeGroup": [
                {
                  "OutcomeGroupId": "OG000",
                  "OutcomeGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
                  "OutcomeGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks"
                },
                {
                  "OutcomeGroupId": "OG001",
                  "OutcomeGroupTitle": "Chemotherapy Alone",
                  "OutcomeGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed"
                }
              ]
            },
            "OutcomeDenomList": {
              "OutcomeDenom": [
                {
                  "OutcomeDenomUnits": "Participants",
                  "OutcomeDenomCountList": {
                    "OutcomeDenomCount": [
                      {
                        "OutcomeDenomCountGroupId": "OG000",
                        "OutcomeDenomCountValue": "0"
                      },
                      {
                        "OutcomeDenomCountGroupId": "OG001",
                        "OutcomeDenomCountValue": "0"
                      }
                    ]
                  }
                }
              ]
            }
          }
        ]
      }
    },
    "AdverseEventsModule": {
      "EventsFrequencyThreshold": "0",
      "EventsTimeFrame": "1 year and 5 months",
      "EventGroupList": {
        "EventGroup": [
          {
            "EventGroupId": "EG000",
            "EventGroupTitle": "Viagenpumatucel-L Plus Metronomic Cyclophosphamide",
            "EventGroupDescription": "Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.\n\nViagenpumatucel-L: Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig\n\nMetronomic Cyclophosphamide: One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks",
            "EventGroupDeathsNumAffected": "7",
            "EventGroupDeathsNumAtRisk": "43",
            "EventGroupSeriousNumAffected": "17",
            "EventGroupSeriousNumAtRisk": "43",
            "EventGroupOtherNumAffected": "19",
            "EventGroupOtherNumAtRisk": "43"
          },
          {
            "EventGroupId": "EG001",
            "EventGroupTitle": "Chemotherapy Alone",
            "EventGroupDescription": "Patients will be treated with a physician's choice regimen until progression.\n\nPhysician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed): Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:\n\nVinorelbine\nErlotinib\nGemcitabine\nPaclitaxel\nDocetaxel\nPemetrexed",
            "EventGroupDeathsNumAffected": "0",
            "EventGroupDeathsNumAtRisk": "20",
            "EventGroupSeriousNumAffected": "8",
            "EventGroupSeriousNumAtRisk": "20",
            "EventGroupOtherNumAffected": "9",
            "EventGroupOtherNumAtRisk": "20"
          }
        ]
      },
      "SeriousEventList": {
        "SeriousEvent": [
          {
            "SeriousEventTerm": "Febrile Neutropenia",
            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
            "SeriousEventSourceVocabulary": "MedDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Lymphadenopathy",
            "SeriousEventOrganSystem": "Blood and lymphatic system disorders",
            "SeriousEventSourceVocabulary": "MedDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cardiac Arrest",
            "SeriousEventOrganSystem": "Cardiac disorders",
            "SeriousEventSourceVocabulary": "MedDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Inappropriate Antidiuretic Hormone Secretion",
            "SeriousEventOrganSystem": "Endocrine disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Abdominal Pain",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Ileus",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Oesophagitis Ulcerative",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Vomiting",
            "SeriousEventOrganSystem": "Gastrointestinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Disease Progression",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pain",
            "SeriousEventOrganSystem": "General disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Oral Candidiasis",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pneumonia",
            "SeriousEventOrganSystem": "Infections and infestations",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cervical Vertebral Fracture",
            "SeriousEventOrganSystem": "Injury, poisoning and procedural complications",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Humerus Fracture",
            "SeriousEventOrganSystem": "Injury, poisoning and procedural complications",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Dehydration",
            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Hyponatraemia",
            "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Back Pain",
            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Neck Pain",
            "SeriousEventOrganSystem": "Musculoskeletal and connective tissue disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Malignant Pleural Effusion",
            "SeriousEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Cerebrovascular Accident",
            "SeriousEventOrganSystem": "Nervous system disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Mental Status Changes",
            "SeriousEventOrganSystem": "Psychiatric disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Acute Respiratory Failure",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Chronic Obstructive Pulmonary Disease",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Dyspnoea",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Respiratory Failure",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Pulmonary Embolism",
            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "2",
                  "SeriousEventStatsNumAffected": "2",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Deep Vein Thrombosis",
            "SeriousEventOrganSystem": "Vascular disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "SeriousEventTerm": "Superior Vena Cava Syndrome",
            "SeriousEventOrganSystem": "Vascular disorders",
            "SeriousEventSourceVocabulary": "medDRA v16.1",
            "SeriousEventAssessmentType": "Systematic Assessment",
            "SeriousEventStatsList": {
              "SeriousEventStats": [
                {
                  "SeriousEventStatsGroupId": "EG000",
                  "SeriousEventStatsNumEvents": "0",
                  "SeriousEventStatsNumAffected": "0",
                  "SeriousEventStatsNumAtRisk": "43"
                },
                {
                  "SeriousEventStatsGroupId": "EG001",
                  "SeriousEventStatsNumEvents": "1",
                  "SeriousEventStatsNumAffected": "1",
                  "SeriousEventStatsNumAtRisk": "20"
                }
              ]
            }
          }
        ]
      },
      "OtherEventList": {
        "OtherEvent": [
          {
            "OtherEventTerm": "Cough",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "5",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "5",
                  "OtherEventStatsNumAffected": "4",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Dyspnoea",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "15",
                  "OtherEventStatsNumAffected": "11",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "8",
                  "OtherEventStatsNumAffected": "7",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Nasal Congestion",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "3",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Interstitial Lung Disease",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Oropharyngeal Pain",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pleuritic Pain",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rhinorrhea",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Upper Respiratory Tract Congestion",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Wheezing",
            "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Alopecia",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Blister",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Eczema",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Night Sweats",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Onychomadesis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Pruritis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "3",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Rash",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Deep Vein Thrombosis",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Hot Flush",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "2",
                  "OtherEventStatsNumAffected": "2",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          },
          {
            "OtherEventTerm": "Superior Vena Cava Syndrome",
            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
            "OtherEventSourceVocabulary": "medDRA v16.1",
            "OtherEventAssessmentType": "Systematic Assessment",
            "OtherEventStatsList": {
              "OtherEventStats": [
                {
                  "OtherEventStatsGroupId": "EG000",
                  "OtherEventStatsNumEvents": "0",
                  "OtherEventStatsNumAffected": "0",
                  "OtherEventStatsNumAtRisk": "43"
                },
                {
                  "OtherEventStatsGroupId": "EG001",
                  "OtherEventStatsNumEvents": "1",
                  "OtherEventStatsNumAffected": "1",
                  "OtherEventStatsNumAtRisk": "20"
                }
              ]
            }
          }
        ]
      }
    },
    "MoreInfoModule": {
      "CertainAgreement": {
        "AgreementPISponsorEmployee": "No",
        "AgreementRestrictiveAgreement": "No"
      },
      "PointOfContact": {
        "PointOfContactTitle": "Lori McDermott",
        "PointOfContactOrganization": "Clinical Development",
        "PointOfContactEMail": "lmcdermott@heatbio.com",
        "PointOfContactPhone": "919-794-8950"
      }
    }
  },
  "DocumentSection": {
    "LargeDocumentModule": {
      "LargeDocList": {
        "LargeDoc": [
          {
            "LargeDocTypeAbbrev": "Prot_SAP",
            "LargeDocHasProtocol": "Yes",
            "LargeDocHasSAP": "Yes",
            "LargeDocHasICF": "No",
            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
            "LargeDocDate": "October 29, 2014",
            "LargeDocUploadDate": "04/26/2019 13:08",
            "LargeDocFilename": "Prot_SAP_000.pdf"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008175",
            "ConditionMeshTerm": "Lung Neoplasms"
          },
          {
            "ConditionMeshId": "D000002289",
            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000012142",
            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
          },
          {
            "ConditionAncestorId": "D000013899",
            "ConditionAncestorTerm": "Thoracic Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000008171",
            "ConditionAncestorTerm": "Lung Diseases"
          },
          {
            "ConditionAncestorId": "D000012140",
            "ConditionAncestorTerm": "Respiratory Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000002283",
            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
          },
          {
            "ConditionAncestorId": "D000001984",
            "ConditionAncestorTerm": "Bronchial Neoplasms"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M10324",
            "ConditionBrowseLeafName": "Lung Neoplasms",
            "ConditionBrowseLeafAsFound": "Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4698",
            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M2737",
            "ConditionBrowseLeafName": "Adenocarcinoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M1687",
            "ConditionBrowseLeafName": "Adenocarcinoma of Lung",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4686",
            "ConditionBrowseLeafName": "Carcinoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14131",
            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15810",
            "ConditionBrowseLeafName": "Thoracic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10320",
            "ConditionBrowseLeafName": "Lung Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14129",
            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4692",
            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4412",
            "ConditionBrowseLeafName": "Bronchial Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3520",
            "ConditionBrowseLeafName": "Lung Adenocarcinoma",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC08",
            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "C000056507",
            "InterventionMeshTerm": "Gemcitabine"
          },
          {
            "InterventionMeshId": "D000017239",
            "InterventionMeshTerm": "Paclitaxel"
          },
          {
            "InterventionMeshId": "D000077235",
            "InterventionMeshTerm": "Vinorelbine"
          },
          {
            "InterventionMeshId": "D000077143",
            "InterventionMeshTerm": "Docetaxel"
          },
          {
            "InterventionMeshId": "D000003520",
            "InterventionMeshTerm": "Cyclophosphamide"
          },
          {
            "InterventionMeshId": "D000068437",
            "InterventionMeshTerm": "Pemetrexed"
          },
          {
            "InterventionMeshId": "D000069347",
            "InterventionMeshTerm": "Erlotinib Hydrochloride"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000972",
            "InterventionAncestorTerm": "Antineoplastic Agents, Phytogenic"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          },
          {
            "InterventionAncestorId": "D000050257",
            "InterventionAncestorTerm": "Tubulin Modulators"
          },
          {
            "InterventionAncestorId": "D000050256",
            "InterventionAncestorTerm": "Antimitotic Agents"
          },
          {
            "InterventionAncestorId": "D000050258",
            "InterventionAncestorTerm": "Mitosis Modulators"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000007166",
            "InterventionAncestorTerm": "Immunosuppressive Agents"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          },
          {
            "InterventionAncestorId": "D000018501",
            "InterventionAncestorTerm": "Antirheumatic Agents"
          },
          {
            "InterventionAncestorId": "D000018906",
            "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
          },
          {
            "InterventionAncestorId": "D000000477",
            "InterventionAncestorTerm": "Alkylating Agents"
          },
          {
            "InterventionAncestorId": "D000019653",
            "InterventionAncestorTerm": "Myeloablative Agonists"
          },
          {
            "InterventionAncestorId": "D000000964",
            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
          },
          {
            "InterventionAncestorId": "D000000963",
            "InterventionAncestorTerm": "Antimetabolites"
          },
          {
            "InterventionAncestorId": "D000000998",
            "InterventionAncestorTerm": "Antiviral Agents"
          },
          {
            "InterventionAncestorId": "D000000890",
            "InterventionAncestorTerm": "Anti-Infective Agents"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          },
          {
            "InterventionAncestorId": "D000005493",
            "InterventionAncestorTerm": "Folic Acid Antagonists"
          },
          {
            "InterventionAncestorId": "D000019384",
            "InterventionAncestorTerm": "Nucleic Acid Synthesis Inhibitors"
          },
          {
            "InterventionAncestorId": "D000047428",
            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M264",
            "InterventionBrowseLeafName": "Pemetrexed",
            "InterventionBrowseLeafAsFound": "New",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M5879",
            "InterventionBrowseLeafName": "Cyclophosphamide",
            "InterventionBrowseLeafAsFound": "Months",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M113169",
            "InterventionBrowseLeafName": "Gemcitabine",
            "InterventionBrowseLeafAsFound": "Capsules",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M16512",
            "InterventionBrowseLeafName": "Vaccines",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M18689",
            "InterventionBrowseLeafName": "Paclitaxel",
            "InterventionBrowseLeafAsFound": "From",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M231",
            "InterventionBrowseLeafName": "Albumin-Bound Paclitaxel",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1668",
            "InterventionBrowseLeafName": "Docetaxel",
            "InterventionBrowseLeafAsFound": "Administration",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M1710",
            "InterventionBrowseLeafName": "Vinorelbine",
            "InterventionBrowseLeafAsFound": "Metastases",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M398",
            "InterventionBrowseLeafName": "Erlotinib Hydrochloride",
            "InterventionBrowseLeafAsFound": "Target",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M25350",
            "InterventionBrowseLeafName": "Tubulin Modulators",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M25349",
            "InterventionBrowseLeafName": "Antimitotic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9364",
            "InterventionBrowseLeafName": "Immunosuppressive Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M19757",
            "InterventionBrowseLeafName": "Antirheumatic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M20095",
            "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2972",
            "InterventionBrowseLeafName": "Alkylating Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3433",
            "InterventionBrowseLeafName": "Antimetabolites",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3466",
            "InterventionBrowseLeafName": "Antiviral Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3366",
            "InterventionBrowseLeafName": "Anti-Infective Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M7770",
            "InterventionBrowseLeafName": "Folic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M16698",
            "InterventionBrowseLeafName": "Vitamin B Complex",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M7771",
            "InterventionBrowseLeafName": "Folic Acid Antagonists",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M24973",
            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T447",
            "InterventionBrowseLeafName": "Folinic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T446",
            "InterventionBrowseLeafName": "Folic Acid",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T448",
            "InterventionBrowseLeafName": "Folate",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "T475",
            "InterventionBrowseLeafName": "Vitamin B9",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "ARhu",
            "InterventionBrowseBranchName": "Antirheumatic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "Micro",
            "InterventionBrowseBranchName": "Micronutrients"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "Vi",
            "InterventionBrowseBranchName": "Vitamins"
          }
        ]
      }
    }
  }
}